Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Terminated NCT05065957

Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer

Conditions: Biliary Tract Cancer

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2, PHASE3
Enrollment: 19
Sponsor: InnoPharmax Inc.

Location: Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung City

Summary

The primary objective are: To assess the safety and tolerability of the combination of D07001-softgel capsules and Xeloda/TS-1. To evaluate the efficacy of the combination of D07001-softgel capsules and Xeloda/TS-1, as assessed by disease control rate (DCR).

Eligibility Criteria

Inclusion Criteria: 1. Male or female patients aged 18 years or older at screening (aged 20 years or older in Taiwan) 2. Histopathological or cytologic diagnosis of unresectable metastatic or locally advanced BTC (cholangiocarcinoma, gallbladder cancer or ampullary carcinoma) 3. Subject must have failed from first line gemcitabine and cisplatin-based chemotherapy 4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-1 5. Life expectancy is \>12 weeks 6. Adequate bone marrow function, demonstrated by: 1. Absolute neutrophil count (ANC) ≥1,500 cell/mm3 2. Platelet count ≥ 100,000 cells/mm3 3. Hemoglobin ≥ 9 g/dL 7. Adequate liver function, demonstrated by: 1. Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 x upper limit of normal (ULN), or ≤5.0 x ULN in the case of liver metastases 2. Total bilirubin ≤1.5 x ULN 3. Albumin ≥3.0 g/dL 4. International normalized ratio (INR) \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05065957). StuddyBuddy aggregates publicly available trial information.